Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| PLUR | 8-K | neutral | 3/10 | Pluri Inc. announced that its majority-owned subsidiary Ever After Foods Ltd. (EAF) agreed to acquire all outstanding sh | Aug 17, 2026 |
| CUE | CLUSTER | bearish | 6/10 | CEO Shao-Lee Lin sold ~$1.6M of CUE shares in open-market sales last week, and VP Meluzio sold ~$169K, both after exerci | Aug 17, 2026 |
| ARDX | 8-K | neutral | 2/10 | Ardelyx disclosed the resignation of Chief Commercial Officer Eric Foster, effective August 28, 2026, to pursue a new op | Aug 17, 2026 |
| PFE | INSIDER-BUY | bullish | 5/10 | Pfizer Chairman & CEO Albert Bourla made an open-market purchase of $1.0M worth of shares at $26.34 on August 12, 2026, | Aug 17, 2026 |
| NMRA | 144 | bearish | 5/10 | Aurora Daljit Singh, an officer of Neumora Therapeutics, filed a Form 144 notice of intent to sell 146,706 shares of com | Aug 17, 2026 |
| AVXL | DEFA14A | mixed | 7/10 | Anavex Life Sciences management launched a website, www.voteanavex.com, to solicit shareholder support ahead of the Sept | Aug 17, 2026 |
| IVVD | 144 | neutral | 2/10 | Invivyd director William E. Duke filed a Form 144 to sell 40,800 shares (estimated value ~$29,413) in a non-discretionar | Aug 17, 2026 |
| ORKA | CLUSTER | neutral | 2/10 | Two senior insiders at Oruka Therapeutics (CMO and General Counsel) executed large-derivative exercises and sold shares | Aug 17, 2026 |
| CURX | 8-K | neutral | 3/10 | Curanex Pharmaceuticals filed a Certificate of Amendment with the Nevada Secretary of State to effect a 1-for-20 reverse | Aug 17, 2026 |
| MAZE | 3 | neutral | 1/10 | Paula A. Johnson filed a Form 3 initial statement of beneficial ownership with Maze Therapeutics, Inc., indicating her a | Aug 17, 2026 |
| CHRS | PRESS-RELEASE | neutral | 4/10 | Coherus Oncology announced a special dividend of contingent value rights (CVRs) tied to the future sale of its remaining | Aug 17, 2026 |
| RCKT | CLUSTER | neutral | 4/10 | Three Rocket Pharmaceuticals insiders, including the CEO and COO, sold a total of $154K in open-market sales over a 7-da | Aug 17, 2026 |
| RYTM | CLUSTER | neutral | 4/10 | Three Rhythm Pharmaceuticals executives sold a total of $9.77M in open-market stock within a week of the company's stron | Aug 17, 2026 |
| ADPT | 144 | bearish | 4/10 | Director Peter Neupert filed a Form 144 notice to sell up to 124,690 shares of Adaptive Biotechnologies, valued at appro | Aug 17, 2026 |
| AKAN | 6-K | bearish | 7/10 | Akanda Corp. disclosed it received a Nasdaq extension through December 13, 2026, to regain compliance with the minimum $ | Aug 17, 2026 |
| KURA | INSIDER-BUY | bullish | 7/10 | Kura Oncology CEO Troy Wilson purchased 100,000 shares worth $1.11M on the open market at $11.12/share, representing a m | Aug 17, 2026 |
| INDP | S-3 | bearish | 7/10 | Indaptus Therapeutics filed an S-3 registration statement to register 58,895,000 shares of common stock for resale by se | Aug 17, 2026 |
| MEHA | 8-K | bearish | 8/10 | Functional Brands reported Q2 2026 revenue of $1.87M, up ~2% YoY, but the operating loss widened to $1.3M from $0.16M, d | Aug 17, 2026 |
| MBX | 144 | neutral | 3/10 | Former officer Peter K. Hawryluk filed a Form 144 notice of intent to sell 3,745 MBX shares (~$256K at filing). The shar | Aug 17, 2026 |
| ERAS | 144 | neutral | 3/10 | Erasca Foundation, a major affiliate holder, filed a Form 144 on August 17, 2026, signaling intent to sell 8,333 shares | Aug 17, 2026 |
| AZN | 6-K | bullish | 6/10 | AstraZeneca reported two clinical trial updates on the same day: (1) Enhertu (trastuzumab deruxtecan) achieved a statist | Aug 17, 2026 |
| CANF | 6-K | neutral | 4/10 | Can-Fite BioPharma announced new preclinical findings showing namodenoson enhances gemcitabine's anti-cancer effect in p | Aug 17, 2026 |
| AVXL | DEFA14A | mixed | 6/10 | Anavex Life Sciences management filed this DEFA14A (soliciting material) to urge stockholders to vote the WHITE proxy ca | Aug 17, 2026 |
| FULC | 425 | bullish | 8/10 | Fulcrum Therapeutics (FULC) and Slate Medicines announced a definitive merger agreement in which Fulcrum will acquire Sl | Aug 17, 2026 |
| TRIB | 6-K | neutral | 4/10 | Trinity Biotech's Trinovium subsidiary announced a strategic collaboration with hyperscale data center operator Echelon | Aug 17, 2026 |
| FULC | 425 | bearish | 7/10 | Fulcrum Therapeutics (FULC) filed a Rule 425 transcript of a joint conference call with Slate Medicines, confirming the | Aug 17, 2026 |
| STLN | INSIDER-BUY | neutral | 3/10 | A 10% owner of Starling Oncology bought $78K in shares open-market at $6.54, while selling a trivial $624. The net $78K | Aug 17, 2026 |
| NSRX | 6-K | neutral | 5/10 | Nasus Pharma reported Q2 2026 results: net loss widened to $5.9M (from $1.3M in H1 2025) as R&D spend surged 796% to $2. | Aug 17, 2026 |
| GLMD | 6-K | bullish | 6/10 | Galmed Pharmaceuticals announced pre-clinical results showing that Aramchol combined with enzalutamide (Xtandi) produced | Aug 17, 2026 |
| BBIO | 8-K | neutral | 4/10 | KKR Genetic Disorder L.P. is selling 5,000,000 shares of BridgeBio common stock at $78.00 per share in an underwritten s | Aug 17, 2026 |